DE3238569C2 - - Google Patents

Info

Publication number
DE3238569C2
DE3238569C2 DE3238569A DE3238569A DE3238569C2 DE 3238569 C2 DE3238569 C2 DE 3238569C2 DE 3238569 A DE3238569 A DE 3238569A DE 3238569 A DE3238569 A DE 3238569A DE 3238569 C2 DE3238569 C2 DE 3238569C2
Authority
DE
Germany
Prior art keywords
monohydrate
beclomethasone dipropionate
water
micronized
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE3238569A
Other languages
German (de)
English (en)
Other versions
DE3238569A1 (de
Inventor
John Harold Hertford Hertfordshire Gb Hunt
John Malcolm Meldreth Cambridgeshire Gb Padfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE3238569A1 publication Critical patent/DE3238569A1/de
Application granted granted Critical
Publication of DE3238569C2 publication Critical patent/DE3238569C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE19823238569 1981-10-19 1982-10-18 Steroid-verbindung und diese enthaltende pharmazeutische zusammensetzungen Granted DE3238569A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8131425 1981-10-19

Publications (2)

Publication Number Publication Date
DE3238569A1 DE3238569A1 (de) 1983-05-05
DE3238569C2 true DE3238569C2 (enExample) 1991-01-31

Family

ID=10525238

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19823238569 Granted DE3238569A1 (de) 1981-10-19 1982-10-18 Steroid-verbindung und diese enthaltende pharmazeutische zusammensetzungen

Country Status (22)

Country Link
US (1) US4866051A (enExample)
JP (1) JPS5890599A (enExample)
KR (1) KR890000664B1 (enExample)
AU (1) AU551471B2 (enExample)
BE (1) BE894725A (enExample)
CA (1) CA1189853A (enExample)
CH (1) CH652134A5 (enExample)
DE (1) DE3238569A1 (enExample)
DK (1) DK168389B1 (enExample)
DO (1) DOP1990004774A (enExample)
ES (1) ES8404374A1 (enExample)
FI (1) FI73128C (enExample)
FR (1) FR2514769B1 (enExample)
HK (1) HK100989A (enExample)
IE (1) IE54170B1 (enExample)
IT (1) IT1196553B (enExample)
MY (1) MY8700910A (enExample)
NL (1) NL8204013A (enExample)
NZ (1) NZ202212A (enExample)
PT (1) PT75692A (enExample)
SE (1) SE454356B (enExample)
ZA (1) ZA827601B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
WO1997001341A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal mast cell stabilizers and topical nasal steroids
US5987746A (en) * 1996-02-21 1999-11-23 Medtronic, Inc. Method of making medical electrical lead
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DK1808438T3 (da) * 1999-06-29 2014-10-27 Mannkind Corp Rensning og stabilisering af peptid og proteiner i lægemidler
CA2382133C (en) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
TW200300696A (en) * 2001-11-01 2003-06-16 Inhale Therapeutic Syst Spray drying methods and related compositions
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP4532281B2 (ja) * 2002-11-08 2010-08-25 株式会社カネカ エルゴステロールの分離方法
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
ES2584867T3 (es) * 2004-01-12 2016-09-29 Mannkind Corporation Un método que reduce los niveles séricos de proinsulina en diabéticos de tipo 2
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
EP2314298B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Microparticles comprising diketopiperazine salts for drug delivery
US20060204601A1 (en) * 2005-03-09 2006-09-14 Palu Afa K Formulations and methods for preventing and treating substance abuse and addiction
WO2006096906A1 (en) * 2005-03-18 2006-09-21 Nanomaterials Technology Pte Ltd Inhalable drug
AU2006290870B2 (en) 2005-09-14 2013-02-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
AU2007238114B2 (en) * 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
CN101951957A (zh) * 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
GB0806873D0 (en) * 2008-04-16 2008-05-21 Breath Ltd Steroid nebuliser formulation
CN103252007B (zh) 2008-06-13 2016-06-22 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
GB0914231D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Dry powder inhaler formulations
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
CN105451716A (zh) 2013-07-18 2016-03-30 曼金德公司 热稳定性干粉药物组合物和方法
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
IT201800007527A1 (it) * 2018-07-26 2020-01-26 Sofar Spa Composizione contenente beclometasone per la prevenzione e il trattamento di prostatiti batteriche e vaginiti

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047519A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡,21-diesters of 11,17,21-trihydroxy steroid compounds
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
CH622811A5 (enExample) * 1974-03-27 1981-04-30 Plurichemie Anstalt
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
IT1121513B (it) * 1979-05-28 1986-04-02 Chiesi Farma Spa Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
ATE3774T1 (de) * 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
PT71309A (en) * 1980-05-27 1980-06-01 Hovione Sociedade Quimica Lda Process of selective
PT73772B (en) * 1980-10-06 1983-10-14 Glaxo Group Ltd Topically administrable pharmaceutical compositions containing anti-inflammatory steroids
US4391755A (en) * 1982-01-18 1983-07-05 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
DK336485A (da) * 1984-07-25 1986-01-26 Hovione Int Ltd Fremgangsmaade til fremstilling af et diisopropylaetersolvat af beclomethason-17,21-dipropionat
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids

Also Published As

Publication number Publication date
IE54170B1 (en) 1989-07-05
FI823561L (fi) 1983-04-20
FR2514769A1 (fr) 1983-04-22
BE894725A (fr) 1983-04-18
FI73128B (fi) 1987-05-29
CH652134A5 (de) 1985-10-31
KR840002007A (ko) 1984-06-11
IT8249294A0 (it) 1982-10-18
KR890000664B1 (ko) 1989-03-22
IE822514L (en) 1983-04-19
FI823561A0 (fi) 1982-10-18
DK168389B1 (da) 1994-03-21
ZA827601B (en) 1983-09-28
SE8205904D0 (sv) 1982-10-18
ES516611A0 (es) 1984-05-01
JPS5890599A (ja) 1983-05-30
IT8249294A1 (it) 1984-04-18
AU551471B2 (en) 1986-05-01
IT1196553B (it) 1988-11-16
PT75692A (en) 1982-11-01
DOP1990004774A (es) 1996-02-02
NZ202212A (en) 1986-01-24
SE8205904L (sv) 1983-04-20
DE3238569A1 (de) 1983-05-05
JPH0424358B2 (enExample) 1992-04-24
HK100989A (en) 1989-12-29
FI73128C (fi) 1987-09-10
MY8700910A (en) 1987-12-31
US4866051A (en) 1989-09-12
ES8404374A1 (es) 1984-05-01
AU8946082A (en) 1984-05-03
DK461182A (da) 1983-04-20
FR2514769B1 (fr) 1985-08-30
SE454356B (sv) 1988-04-25
NL8204013A (nl) 1983-05-16
CA1189853A (en) 1985-07-02

Similar Documents

Publication Publication Date Title
DE3238569C2 (enExample)
EP0126379B1 (de) Zweiphasenformulierung
DE69816997T2 (de) Mittel, die fein verteilte, kristalline budenosid-partikel enthalten
DE69426934T2 (de) Verfahren zur konditionierung von substanzen
DE69109284T2 (de) Verwendung von fluorierten löslichen tensiden zur herstellung von aerosolarzneimitteln mit dosierter abgabe.
EP0212537B1 (de) Verfahren zur Herstellung einer stabilen Modifikation von Torasemid sowie Arzneimittel enthaltend Torasemid
DE69828886T3 (de) Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, verfahren zur herstellung der formulierung sowie anwendung derselben
DE69307977T2 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
DE69026555T2 (de) Feste zubereitung von aktivem vitamin d3 mit verbesserter stabilität
DE2703119C2 (enExample)
DE69839275T2 (de) Neue formulierung zur inhalation mit einer bulkdichte zwischen 0,28 und 0,38 g/ml enthaltend budensonide
EP1785422B1 (de) Kristallines Mikronisat des Tiotropiumbromids
DE69001573T2 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
DD201974A5 (de) Verfahren zur herstellung von festen arzneizubereitungen enthaltend nifedipin
DE69821119T2 (de) Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, mit formoterol
GB2107715A (en) Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
DE69817774T2 (de) Trägerstoff für trockenpulverinhalator, verfahren zu dessen herstellung und diesen enthaltende arzneimittel
DE60311665T2 (de) Pharmazeutische zusammensetzungen
EP0931087B1 (de) Neue pyranosidderivate
DE69309461T2 (de) Zusammensetzung zur Beschleunigung der Wundheilung
DE69734460T2 (de) Verfahren zur kristallisierung eines tetrahydropyridinderivates und die so erhaltenen kristallinen formen
DE3833446A1 (de) Verfahren zur herstellung von arzneimittelwirkstoff-partikeln mit verbesserten fliess-, lager- und formulierungseigenschaften sowie arzneimittel, die diese arzneimittelwirkstoff-partikeln enthalten
DE2831419A1 (de) Dispersion oder suspension aus lecithin oder einem sorbitan- oder sorbit-ester in treibmittel 12
DE2930039A1 (de) Entzuendungshemmendes mittel
DE3228384A1 (de) Verfahren zur verbesserung der loeslichkeit eines sulfonylharnstoffderivates und dieses enthaltende pharmazeutische zubereitungen

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8363 Opposition against the patent
8331 Complete revocation